← Eichor
Study identifier: NCT05640609 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Condition: Stomach Neoplasm  ·  Sponsor: West China Hospital

PhasePhase 1/Phase 2
Planned participants57
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

The median survival time of first-line chemotherapy for advanced gastric cancer is about one year, and the treatment is still facing the bottleneck. This is a one-arm, open and prospective phase II clinical study. Recruit patients who have been diagnosed with advanced or metastatic adenocarcinoma of the stomach and gastroesophageal junction and have not received systematic treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Liu Ming, Professor  ·  +86 18980606324  ·  liuming629@wchscu.cn

Dai Ruihong, doctor  ·  +86 18715779637  ·  760173632@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Liu MingChengdu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05640609